comparemela.com

Latest Breaking News On - Osei group aktie - Page 1 : comparemela.com

Nxera Pharma is the New Name for Sosei Group

01.04.2024 - New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing in science and technologySosei . Seite 1

Chris cargillNxera pharmaIdorsia pharmaceuticals japanNxera pharma united kingdomNxera pharma co ltdIdorsia pharmaceuticals japan ltdNxera pharma japan co ltdSosei group corporationIdorsia pharmaceuticals korea co ltdNxera pharma korea co ltdSosei group to nxera pharmaHeptares therapeutics ltdSosei groupHeptares therapeuticsPharmaceuticals japanLife itself

Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office Seite 1

16.02.2024 - Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of Directors resolved to change the corporate names of . Seite 1

Nxera pharma united kingdomIdorsia pharmaceuticals japan ltdIdorsia pharmaceuticals korea co ltdNxera pharma japan co ltdSosei coSosei group corporationNxera pharma co ltdNxera pharma korea co ltdHeptares therapeutics ltdOrdinary general meetingSosei group chartOsei group kursOsei group aktie

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

13.02.2024 - Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023. The . Seite 1

United kingdomSosei heptaresChris cargillSosei groupSosei group corporation heptaresSosei group corporationSosei group chartOsei group kursOsei group aktie

Sosei Heptares President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023 Seite 1

18.10.2023 - Tokyo, Japan, and Cambridge, UK, 18 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based drug design (SBDD) and . Seite 1

United kingdomChris cargillSosei heptaresTokyo stock exchangeTokyo stockSosei group chartOsei group kursOsei group aktie

Sosei Heptares partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults Seite 1

12.09.2023 - NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into . Seite 1

United kingdomSosei heptaresNeurocrine biosciencesSosei heptareEiryw robertsMatt barnesNeurocrine biosciences incSosei group corporation the companySosei group corporationChief medical officerHeptares therapeuticsSosei group chartOsei group kursOsei group aktie

vimarsana © 2020. All Rights Reserved.